Operator

Ladies and gentlemen, thank you for standing by, and welcome to Niagen Bioscience Inc.'s First Quarter 2026 Earnings Conference Call. My name is Karina, and I will be the conference operator today.

[Operator Instructions]

As a reminder, this conference call is being recorded. Earlier today, Niagen Bioscience issued a press release announcing its financial results for the first quarter of 2026. If you have not reviewed this information, it is available within the Investor Relations section of Niagen Bioscience's website at www.niagenbioscience.com.

I would now like to turn the call over to Lauren Borzansky, Assistant Controller. Please go ahead.

Lauren Rittman-Borzansky

Good afternoon, and welcome to Niagen Bioscience Inc.'s First Quarter 2026 Conference Call. Joining me today are our Chief Executive Officer, Rob Fried; Chief Financial Officer, Ozan Pamir; and Senior Vice President of Scientific and Regulatory Affairs, Dr. Andrew Shao. Dr. Shao will be joining the call for Q&A.

Before we begin, I'd like to remind everyone that today's call may include forward-looking statements. These statements relate to, among other things, our research and development activities, clinical trial plans and timing, regulatory filings, expansion into new markets, business development opportunities and our expected financial and operating performance. These statements are based on our current expectations as of today and are subject to risks and uncertainties that could cause actual results to differ materially.

For